In what represents just the third PCT filing to have been published in the name of Zurich, Switzerland-based Siva Health AG, protection is sought for a computer-implemented method of classifying an individual suffering from chronic cough.
Scientists at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have described tricyclic compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK1/cyclin B and/or CDK2/cyclin E1 and/or CDK4/cyclin D3 and/or CDK6/cyclin D3 inhibitors, reported to be useful for the treatment of cancer.
Virginia Commonwealth University has identified cholestenoic acid derivatives reported to be useful for the treatment of cancer, sepsis, atherosclerosis and nonalcoholic fatty liver disease (NAFLD; metabolic dysfunction-associated steatotic liver disease [MASLD]).
Insilico Medicine Hong Kong Ltd. has synthesized ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer and viral infection.
Dana-Farber Cancer Institute Inc. has disclosed covalent inhibitors of serine/threonine-protein kinase A-Raf (ARAF) reported to be useful for the treatment of carcinoma and melanoma.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators potentially useful for the treatment of epilepsy and depression.
The Chinese National Institutes of Pharmaceutical Research & Development has divulged nitrogen-containing heterocyclic compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
RSS
